Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis
Saved in:
| Published in: | Rheumatology & Autoimmunity |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis
- Characterizing Adherence to a Mobile Health App for Patient-Reported Outcomes in Rheumatoid Arthritis
- The association between bariatric surgery and incident rheumatoid arthritis
- Mycobacterium Intracellulare Infection of the Metacarpophalangeal Joint in a Patient With Rheumatoid Arthritis: A Case Report
- Biologic Therapy Is Associated with Faster Bone Union After the Sauvé–Kapandji Procedure in Patients with Rheumatoid Arthritis
- Herpes Zoster Risk in Rheumatoid Arthritis Patients on Janus Kinase Inhibitors: A 17-Year Experience from Rheumatoid Arthritis Saudi Database (RASD)
- Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination?